Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Myopia News
ARVO Attendees Share Concern Over Present and Future of Vision Research
The tidal wave of sudden cuts and restrictions to funding for vision and ophthalmic research cast a long shadow over the 2025 ARVO meeting. They came up formally and informally throughout the six-d...
Sydnexis Gains EU Approval for Low-Dose Atropine Drops in Pediatric Myopia
Sydnexis announced June 5 that the European Commission had granted marketing authorization for SYD-101, the company’s low-dose atropine formulation for slowing the progression of pediatric myopia. ...
PDUFA Dates for Ophthalmic Drug Candidates, June 2025
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
June 2025 Ophthalmic News Briefs
Bausch + Lomb announced June 4 the US launch of Blink Nourish and Blink Boost over-the-counter lubricating eye drops. Both products are preservative-free and come in a 10 mL multi-dose bottle. Blin...
Sydnexis Gains EU Approval for Low-Dose Atropine Drops in Pediatric Myopia
Sydnexis announced June 5 that the European Commission had granted marketing authorization for SYD-101, the company’s low-dose atropine formulation for slowing the progression of pediatric myopia. ...
iVeena Submits IND to US FDA for Phase II Trial of IVMED-85 in Pediatric Myopia
iVeena Delivery Systems announced May 29 that it had submitted an investigational new drug (IND) application to the US FDA for a Phase II trial of IVMED-85 in pediatric myopia. IVMED-85 is a non-at...
NanoDrops Names Daria Lemann-Blumenthal as CEO
Israel’s NanoDrops announced April 22 that it had appointed Belkin Vision co-founder Daria Lemann-Blumenthal as its new chief executive officer. NanoDrops, founded in 2020, employs a laser-etched p...
April 2025 Ophthalmic News Briefs
Carl Zeiss Meditec announced March 21 the availability in Canada of the Visulas Combi, a green and YAG ophthalmic laser workstation combining photodisruption, photocoagulation, and slit lamp techno...
Sydnexis Receives Positive CHMP Opinion for Low-Dose Atropine Drops in Pediatric Myopia
Sydnexis announced April 1 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended marketing authorization in the European Union for its low-dose ...
Bausch + Lomb Launches Arise Orthokeratology Lens Fitting System in the US
Bausch + Lomb announced March 17 the US launch of Arise, a lens fitting system that uses cloud-based technology to streamline the orthokeratology lens design process. Orthokeratology (ortho-k) lens...
Chinese Regulators Approve Zeiss’ VisuMax 800 with SMILE Pro Software
Germany’s Carl Zeiss Meditec announced Feb. 26 that the National Medical Products Administration in China had approved its updated VisuMax 800 femtosecond refractive laser and related SMILE Pro sof...
US FDA Accepts NDA for Sydnexis’ Low-Dose Atropine for Myopia, Sets PDUFA Date of Oct. 23, 2025
Sydnexis, of Del Mar, California, reported March 11 that the US FDA had accepted its new drug application for SYD-101, a low-dose atropine eye drop to slow the progression of pediatric myopia. The ...
Oculis Leads Latest Ophthalmic Fundraising with $100 Million Offering
Oculis led recent ophthalmic fundraising efforts with an underwritten $100 million offering to advance its pipeline of ocular candidates. Financing announced in the past four weeks totaled $149.1 m...
February 2025 Ophthalmic News Briefs
Outlook Therapeutics reported Jan. 16 the final results of the NORSE EIGHT trial of ONS-5010 (Lytenava), an ophthalmic formulation of bevacizumab for wet AMD. ONS-5010 demonstrated non-inferiority ...
Chinese Regulators Accept Marketing Application for Zhaoke’s Low-Dose Atropine Drop for Myopia
Vyluma announced Jan. 29 that China’s National Medical Products Administration had accepted the marketing application from Zhaoke Ophthalmology for NVK002 (low-dose atropine 0.01%) targeting myopia...
500 Thousand Arizona Students Get Vision Screening Thanks to New Law
Vision health advocacy group Eyes on Learning reported Nov. 14 that around 500 thousand schoolchildren in Arizona are receiving vision screening this year thanks to a new state law and help from lo...
Eyenovia Scraps Phase III Study of Low-Dose Atropine Candidate in Myopia
Eyenovia reported Nov. 15 that it would scrap the Phase III CHAPERONE trial of low-dose atropine in pediatric myopia after an independent data review committee determined that the trial is not meet...
Zeiss Gains US Approval for MEL 90 Excimer Laser
Carl Zeiss Meditec gained US FDA approval on Dec. 4 for its MEL 90 excimer laser, the next-generation iteration of its MEL 80 for LASIK surgery. The MEL 90’s US labeling is for correction of myopia...
Eyenovia Scraps Phase III Study of Low-Dose Atropine in Myopia After Endpoint Missed
Eyenovia reported Nov. 15 that it would scrap the Phase III CHAPERONE trial of low-dose atropine in pediatric myopia after an independent data review committee determined that the trial is not meet...
Orasis Leads Latest Ophthalmic Deals with $78 Million Financing
Orasis Pharmaceuticals led recent ophthalmic fundraising efforts with $78 million in Series D and structured capital to support the launch of Qlosi drops for presbyopia. Financing announced in the ...
Ophthalmologists Compare Myopia Interventions at WOC as Prevalence Soars
Myopia—especially progression of myopia—is getting increased attention from industry and physicians, as evidenced by the sheer number of studies published on the topic. Additionally, data showing h...
ONL Leads Latest Ophthalmic Fundraising with $65M Series D Round
ONL Therapeutics led recent ophthalmic fundraising efforts with a $65 million Series D round to continue advancing its small-molecule Fas inhibitor for retinal disease. Financing announced in the p...
Beacon Leads Latest Ophthalmic Fundraising with $170 Million in Series B
Beacon Therapeutics led recent ophthalmic fundraising efforts with $170 million in Series B funding to advance its candidates for retinal disease. Financing announced in the past four weeks totaled...
July 2024 Ophthalmic News Briefs
Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...
Sydnexis Appoints Perry J. Sternberg as Chief Executive Officer
Sydnexis, of Del Mar, California, announced July 16 that Perry J. Sternberg had been appointed chief executive officer and as a member of the board of directors. He will join the company on Aug. 5,...
Vyluma Plans to Resubmit NDA for Low-Dose Atropine for Myopia after Meeting with US FDA
Vyluma announced June 18 that it had met with the US FDA’s Division of Ophthalmology to discuss resubmitting its new drug application (NDA) for lead compound NVK002, a low-dose formulation of atrop...
June 2024 Ophthalmic News Briefs
Japan’s Nidek announced June 3 that it had launched the RS-1 Glauvas OCT system. The device is CE marked as a Class IIa device. Nidek said the RS-1 Glauvas’ streamlined workflow and advanced analyt...
Dopavision Sees Positive Results in Trial of Photobiomodulation for Myopia
Germany’s Dopavision reported May 28 that its MyopiaX photobiomodulation system targeting myopia showed signals of clinical effect on the rate of progression at six months in a proof-of-concept tri...
EU Accepts Vyluma’s Marketing Application for Low-Dose Atropine in Childhood Myopia
Vyluma reported May 29 that the European Medicines Agency had accepted its marketing application for lead compound NVK002, a low-dose formulation of atropine targeting childhood myopia. NVK002 is a...
2024 APAO Congress Brainstorms How to Expand Access to Eye Care; Companies Showcase Tech Boom
Nearly 7,800 delegates attended the 2024 congress of the Asia-Pacific Academy of Ophthalmology in southern Bali from Feb. 22-25. The 253 sessions and 120 exhibits spread across four floors in two n...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.